What is Affimed?
Founded in 2000 and headquartered in Heidelberg, Baden-Wuerttemberg, Affimed operates at the intersection of biotechnology and precision medicine. The company specializes in the development of novel immuno-oncology therapies designed to harness the power of the human immune system to combat malignant diseases. Its core platform is engineered to provide targeted solutions for specific patient populations, addressing critical unmet needs in cancer care. As a clinical-stage entity, Affimed maintains a rigorous focus on translating complex biological insights into viable, life-saving treatments, positioning itself as a key innovator in the therapeutic oncology space.
How much funding has Affimed raised?
Affimed has raised a total of $86.4M across 2 funding rounds:
Stock Offering
$56M
Debt
$30.4M
Stock Issuance/Offering (2014): $56M, investors not publicly disclosed
Debt (2021): $30.4M led by Silicon Valley Bank
Key Investors in Affimed
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage and investment services, funds management, and business valuation services. The company was founded in 1983 and is headquartered in Santa Clara, California.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Affimed?
With the recent strategic investment now secured, Affimed is poised to enter a critical phase of operational scaling and clinical validation. The company is expected to prioritize the advancement of its lead candidates through late-stage clinical trials, aiming to demonstrate efficacy and safety profiles that meet stringent regulatory standards. Furthermore, the infusion of capital will likely support the expansion of its research infrastructure and the optimization of its proprietary platform, enabling the firm to explore new therapeutic modalities. As the oncology sector continues to evolve, Affimed's strategic roadmap emphasizes long-term value creation through scientific excellence and the successful commercialization of its pipeline, ensuring that its innovative therapies reach the patients who need them most.
See full Affimed company page
